跳至主要内容
临床试验/NCT00092586
NCT00092586已完成3 期

A Multi-center, Double-Blind, Randomized, Placebo-Controlled, Parallel Group, 6-Week Study to Evaluate the Efficacy and Safety of Ezetimibe 10 mg/Day When Added to Ongoing Therapy With a Statin Versus Statin Therapy Alone, in Patients With Hypercholesterolemia Who Have Not Reached National Cholesterol Education Program (NCEP) Adult Treatment Panel (ATP) III Target LDL-Cholesterol Level

Organon and Co0 个研究点目标入组 2,904 人开始时间: 2002年9月最近更新:
适应症
相关药物

试验速览

阶段
3 期
状态
已完成
入组人数
2,904
主要终点
Percent change in LDL-C

研究概览

简要总结

The purpose of this 6-week study is to compare the reduction in specific levels of cholesterol in patients with high cholesterol.

详细描述

The duration of treatment is 6 weeks.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Double (Participant, Investigator)

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • High cholesterol levels that are identified by specific laboratory values

排除标准

  • Active liver disease
  • Any condition or situation which would interfere with participation

结局指标

主要结局

Percent change in LDL-C

次要结局

  • Percentage of patients reaching NCEP ATP III target LDL-C levels

研究者

申办方类型
Industry
责任方
Sponsor

相似试验

Study of an Approved Drug With a Statin (a... | 临床试验